Evidence map›Paper›PMID 26951973›Full record

ArticleThe Korean journal of parasitology2016

Tamoxifen Induces Apoptosis of Leishmania major Promastigotes in Vitro.

Masoud Doroodgar, Mahdi Delavari, Moein Doroodgar, Ali Abbasi, Ali Akbar Taherian, Abbas Doroodgar

Open access · diamondAbstract read
In one paragraph

Article in The Korean journal of parasitology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Antileishmanial Activity of Tamoxifen by Targeting Sphingolipid Metabolism: A Review.Clinical pharmacology : advances and applications · 2022
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Iranian journal of pharmaceutical research : IJPR · 2019
    Article
  10. Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Masoud DoroodgarSchool of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR. Iran.
Mahdi DelavariDepartment of Medical Parasitology, School of Medicine, Kashan University of Medical Sciences, Kashan, IR. Iran.
Moein DoroodgarSchool of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR. Iran.
Ali AbbasiDepartment of Medical Parasitology, School of Medicine, Kashan University of Medical Sciences, Kashan, IR. Iran.
Ali Akbar TaherianDepartment of Pathology and Histology, School of Medicine, Kashan University of Medical Sciences, Kashan, IR. Iran.
Abbas DoroodgarDepartment of Medical Parasitology, School of Medicine, Kashan University of Medical Sciences, Kashan, IR. Iran.
Kashan University of Medical Sciences · IRShahid Beheshti University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tamoxifen is an antagonist of the estrogen receptor and currently used for the treatment of breast cancer. The current treatment of cutaneous leishmaniasis with pentavalent antimony compounds is not satisfactory. Therefore, in this study, due to its antileishmanial activity, effects of tamoxifen on the growth of promastigotes and amastigotes of Leishmania major Iranian strain were evaluated in vitro. Promastigotes and amastigotes were treated with different concentrations (1, 5, 10, 20, and 50 μg/ml) and time periods (24, 48, and 72 hr) of tamoxifen. After tamoxifen treatment, MTT assay (3-[4,5-dimethylthiazol-2-yl]-2,5 biphenyl tetrazolium bromide assay) was used to determine the percentage of live parasites and Graph Pad Prism software to calculate IC50. Flow cytometry was applied to investigate the induction of tamoxifen-induced apoptosis in promastigotes. The half maximal inhibitory concentration (IC50) of tamoxifen on promastigotes was 2.6 μg/ml after 24 hr treatment. Flow cytometry analysis showed that tamoxifen induced early and late apoptosis in Leishmania promastigotes. While after 48 hr in control group the apoptosis was 2.0%, the 50 µg/L concentration of tamoxifen increased it to 59.7%. Based on the in vitro antileishmanial effect, tamoxifen might be used for leishmaniasis treatment; however, further researches on in vivo effects of tamoxifen in animal models are needed.

Indexed as

AnimalsAntiprotozoal AgentsApoptosisCells, CulturedInhibitory Concentration 50Leishmania majorLeishmaniasis, CutaneousMacrophagesMiceTamoxifenAntiprotozoal AgentsTamoxifenamastigoteapoptosisglucantimeLeishmania majorpromastigotetamoxifen

Identifiers

PMID26951973
PMCPMC4792327
OpenAlexW2297259963

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.